MIDODRINE TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
30-11-2022
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
MIDODRINE HYDROCHLORIDE
Tilgjengelig fra:
SANIS HEALTH INC
ATC-kode:
C01CA17
INN (International Name):
MIDODRINE
Dosering :
5MG
Legemiddelform:
TABLET
Sammensetning:
MIDODRINE HYDROCHLORIDE 5MG
Administreringsrute:
ORAL
Enheter i pakken:
15G/50G
Resept typen:
Prescription
Produkt oppsummering:
Active ingredient group (AIG) number: 0123066002; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2022-12-01
Preparatomtale
Page 1 of 23
PRODUCT MONOGRAPH
Pr
MIDODRINE
MIDODRINE HYDROCHLORIDE TABLETS
2.5 MG AND 5 MG
MANUFACTURER’S STANDARD
VASOPRESSOR
Sanis Health Inc.
Date of Preparation:
1 President’s Choice Circle
NOV 30, 2022
Brampton, Ontario
L6Y 5S5
Submission Control No.:
269308
Page 2 of 23
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION
.................................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
6
DRUG INTERACTIONS
...............................................................................................................
12
DOSAGE AND ADMINISTRATION
...........................................................................................
12
OVERDOSAGE
.............................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
14
STORAGE AND STABILITY
......................................................................................................
15
PART II: SCIENTIFIC INFORMATION
........................................................................................
12
PHARMACEUTICAL INFORMATION
......................................................................................
12
CLINICAL TRIALS
......................................................................................................................
18
Les hele dokumentet
